Jeri has served as Intersect ENT’s Chief Financial Officer since 2014, just prior to its initial public offering. She brings over 20 years of experience as a CFO, including taking five companies public. Previously, she served as CFO of several public companies including Amyris (NASDAQ: AMRS), a renewable products company, Symyx Technologies (acquired), a materials science research, instrumentation and software company, Ocera (acquired), a biopharma company, and Cytel (acquired), an immunotherapy company. Ms. Hilleman is a member of the Board of Directors and Audit Committees of NovoCure (NASDAQ: NVCR), a commercial global oncology company, and Minerva Neurosciences (NASDAQ: NERV), a biopharma company focused on central nervous system disorders. She served previously as a member of the Board of Directors and Chair of the Audit Committee of Xenoport, Inc. (acquired), a commercial biopharma company. Jeri holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.